InflaRx to prioritize izicopan as its leading pipeline asset, with a goal of continuing toward Phase 2b readiness in ...
In turn, the company—which is broadly seeking to develop inflammatory drugs targeting the complement system—anticipates ...
A component of the complement system promotes tumor growth by activating myeloid-derived suppressor cells. Figure 1: Multiple pro-inflammatory mediators in the tumor microenvironment increase the ...
Immunotherapy is increasingly becoming standard therapy in cancer, with technology, such as checkpoint inhibitors and cell therapy, raising the efficacy bar in many forms of the disease. But the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback